Parkinson's Disease Dopamine

parkinson's disease, AbbVie

Hope for Parkinson’s disease symptoms is found in late-stage drug study

Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week. Parkinson’s disease, which is lifelong,

Hosted on MSN · 2d

AbbVie's Parkinson's disease drug improves patient mobility in late-stage study

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.

Zacks.com on MSN · 1d

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-2 study, which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).

Parkinson’s Paradox: New Study Reveals Unexpected Dopamine-Tremor Connection

Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...

Research teams make progress against Parkinson's origins and effects

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Ask the doctors: Parkinson’s disease can cause swolling issues

Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...

Outsourcing-pharma1d

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Science Daily2d

Parkinson's News

Caffeine Affects Brain Dopamine Function in Patients With Parkinson's Disease May 28, 2024 — Regular high caffeine consumption affects dopamine function in patients with Parkinson's ...

FierceBiotech2d

AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

GEN7d

Gene and Cell Therapies Take Aim at Parkinson’s Disease

New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.

PharmTech2d

European Biotechs Unlocking Parkinson’s Disease

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

Science Daily2d

Parkinson's Research News

Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system ... disorders attributed to dysfunctions in specific dopamine ... Alzheimer's Drug May Slow Down Cognitive Decline in Dementia ...

GEN8d

Molecular Blueprint Could Redesign Parkinson’s Disease Therapeutics

This pathway is heavily impacted by the loss of dopamine-producing neurons in Parkinson’s disease (PD). Targeting ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results